Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioElectronics' ActiPatch® Chronic Pain Therapy Featured In UK's Leading Daily Mail Newspaper Health Section

BIEL

FREDERICK, Md., April 25, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, announces that its ActiPatch® product's were featured in the United Kingdom's leading Daily Mail's Sunday Health Section, http://www.dailymail.co.uk/health/article-3555221/The-20-pulsing-skin-patch-end-misery-chronic-pain-arthritis-sufferers-diabetics.html. The paper has a circulation of 1.7 million and should increase the awareness of ActiPatch and its benefits for the millions of UK's chronic pain sufferers.

The article, entitled "The £20 pulsing skin patch that could end the misery of chronic pain for arthritis sufferers and diabetics" describes the devices unique technology and reports on the Company's new follow-up Observational Study. The 6-Month study of 254 men and women with different types of chronic pain suggest that it can be highly effective and lead to improved quality life and less dependence on strong painkillers. More than 90% had continued relief averaging a 61% reduction in pain, and nine out of ten had improved sleep. Some 89% were more physically active, 86% reduced their medication use, including prescription opioids, and 65% said they spent less money on over-the-counter painkillers.

The study has been accepted and will be presented at the British Pain Society annual scientific meeting being held from May 10-12 in Harrogate, UK https://www.britishpainsociety.org/2016-asm/.

About BioElectronics Corporation

BioElectronics Corporation is the maker of a leading family of affordable, disposable, drug-free, medical devices. ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. Please visit www.bielcorp.com for clinical evidence and a video http://actipatch.com/why-actipatch/ on how it works.

Contact:   
Grace Holdings
732 335 1152

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-actipatch-chronic-pain-therapy-featured-in-uks-leading-daily-mail-newspaper-health-section-300256531.html

SOURCE BioElectronics Corporation



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today